How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,054 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Systemic lupus erythematosus

Systemic lupus erythematosus Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Proof of concept – note only works for conditions, do not add interventions into the search box! This is a beta ‘proof of concept’ of a fully automated evidence mapping system. It is experimental and therefore the results should be dealt with appropriate scepticism. To understand more of what the system does . Please send feedback to (we will only get better by constructive feedback). For a list

2018 Trip Evidence Maps

2. Belimumab (Benlysta ) - systemic lupus erythematosus

Belimumab (Benlysta ) - systemic lupus erythematosus belimumab | CADTH.ca Find the information you need belimumab belimumab Last Updated: October 1, 2019 Result type: Reports Project Number: SR0616-000 Product Line: Generic Name: Belimumab Brand Name: Benlysta Manufacturer: GlaxoSmithKline Inc. Indications: systemic lupus erythematosus Manufacturer Requested Reimbursement Criteria 1 : For the treatment of SLE patients who meet the following eligibility criteria: Adult patients age 18 years

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

3. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus

Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus The Journal of Rheumatology and Monitoring of Systemic Lupus Erythematosus Canadian Rheumatology Association Recommendations for the Assessment Touma, Evelyne Vinet and Nancy Santesso Reynolds, Earl Silverman, Konstantinos Tselios, Manon Suitner, Murray Urowitz, Zahi Jordi Pardo Pardi, Christine Peschken, Christian Pineau, Janet Pope, Tamara Rader, Jen Legault, Deborah Levy, Lily (...) 26, 2019 - Published by www.jrheum.org Downloaded from 1 Keeling, et al: Canadian SLE recommendations assessment Personal non-commercial use only. The Journal of Rheumatology Copyright © 2018. All rights reserved. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus Stephanie O. Keeling, Zainab Alabdurubalnabi, Antonio Avina-Zubieta, Susan Barr, Louise Bergeron, Sasha Bernatsky, Josiane Bourre-Tessier, Ann Clarke, Alexandra Baril

2018 CPG Infobase

4. Systemic lupus erythematosus

Systemic lupus erythematosus Systemic lupus erythematosus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic lupus erythematosus Last reviewed: February 2019 Last updated: August 2018 Summary Generalised disorder that can affect any system. Symptoms and signs may accumulate over time. The diagnosis is made using criteria recommended by the American College of Rheumatology. Treatments for mild to moderate (...) serositis or arthritis include hydroxychloroquine, non-steroidal anti-inflammatory drugs, or corticosteroids. Treatments for more severe disease may include cyclophosphamide, mycophenolate, or tacrolimus plus corticosteroids. Definition Systemic lupus erythematosus (SLE) is a chronic multi-system disorder that most commonly affects women during their reproductive years. It is characterised by the presence of antinuclear antibodies. In addition to constitutional symptoms, it most frequently involves

2018 BMJ Best Practice

5. Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption

Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption HAS - Medical, Economic and Public Health Assessment Division 1/11 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 PLAQUENIL 200 mg, film-coated tablet B/30 (CIP: 34009 364 (...) 414 6 0) Applicant: SANOFI-AVENTIS France INN hydroxychloroquine sulfate ATC code (2014) P01BA02 (synthetic antimalarials) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned “Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, Adjuvant or preventive treatment of relapses of systemic lupus erythematosus, Prevention of polymorphous light

2015 Haute Autorite de sante

6. Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Belimumab Treatment for Adults with Systemic (...) Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 23, 2018 Project Number: RC0989-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of belimumab for the treatment of adults with systemic lupus erythematosus? What is the cost-effectiveness of belimumab for the treatment of adults with systemic lupus erythematosus? What are the evidence-based

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. (PubMed)

Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence of antinuclear antibodies (ANA), a feature that has been incorporated into multiple classification criteria over the years (...) . In this study, we use a database of cutaneous lupus erythematosus (CLE) patients to determine how many have a negative ANA and meet criteria for SLE using the ACR and/or SLICC criteria.We used a database of 301 biopsy-proven CLE patients that contained information including ANA status and the presence of features of SLE. The database was searched for patients who had a negative ANA and whether or not they met SLE criteria using the ACR and/or SLICC criteria.Of the 301 patients with biopsy-proven CLE

Full Text available with Trip Pro

2019 Arthritis care & research

10. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus

Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus Currently there are 2 different classification criteria for systemic lupus erythematosus (SLE): American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (cSLE (...) ) using a large, multiethnic cohort.We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Prospectively collected data from SickKids' Lupus Database were reviewed/validated against medical records prior to ACR and SLICC scoring based on cumulative symptoms up to the last visit. Sensitivities were compared using McNemar's test. Descriptive statistics were used to identify SLE features unique to each set of criteria and autoantibodies

2019 EvidenceUpdates

11. Belimumab (Benlysta) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE)

Belimumab (Benlysta) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Belimumab (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) | Report | National Health Care Institute You are here: Belimumab (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Search within English part of National Health Care Institute Search Belimumab (...) (Benlysta®) for the treatment of adult patients with auto-antibody-positive systemic lupus erythematosus (SLE) Zorginstituut Nederland has carried out an assessment of the medicinal product subcutaneous belimumab (Benlysta®) and a re-assessment of intravenous belimumab, the latter of which is subject to Conditional Inclusion in the insured standard package. Outcome of assessment of belimumab The Zorginstituut establishes that the addition of both the subcutaneous and the intravenous delivery

2018 National Health Care Institute (Zorginstituut Nederland)

12. A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. (PubMed)

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. 31025748 2019 11 20 1365-2133 180 5 2019 May The British journal of dermatology Br. J. Dermatol. A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. 964-965

Full Text available with Trip Pro

2019 The British journal of dermatology Controlled trial quality: predicted high

13. Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. (PubMed)

Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. Determining the risk of progression to systemic lupus erythematosus (SLE) among patients diagnosed with discoid lupus erythematosus (DLE), and the time frame of this risk, are important clinical questions. Past reports have demonstrated a wide time frame of progression from DLE to SLE, with mean time to progression of approximately 8 years. Using data obtained from an academic (...) lupus centre, we identified 32 patients who progressed from DLE to SLE. In our cohort, we found that the median time to progression from DLE to SLE was 453 days, much sooner than previously reported. We believe this information can help inform clinicians on monitoring visit intervals and how best to counsel patients on SLE progression.© 2019 British Association of Dermatologists.

2019 Clinical & Experimental Dermatology

14. Comment on: Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score (PubMed)

Comment on: Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score [No Abstract Available].

Full Text available with Trip Pro

2018 Saudi medical journal

15. Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score (PubMed)

Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score To elucidate the clinico-laboratory characteristics associated with pediatric systemic lupus erythematosus (pSLE) patients with higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score in a retrospective cohort of pSLE patients.A retrospective study involving 32 pSLE patients was conducted (...) %) patients had active SLE (SLEDAI ≥6), and these patients were significantly associated with heavy pyuria (p=0.004), a high ANA concentration (1:160; p=0.040, 1:320; p=0.006), elevated ESR (p=0.006), low C3 levels (p=0.008), oral ulcers (p=0.010), heavy hematuria (p=0.017) and heavy proteinuria (p=0.017), lupus erythematosus (LE)-nonspecific lesion manifestations (p=0.019) and malar rash (p=0.044).Pediatric systemic lupus erythematosus patients with higher SLEDAI score were most significantly associated

Full Text available with Trip Pro

2018 Saudi medical journal

16. Guideline for the management of adults with Systemic Lupus Erythematosus

Guideline for the management of adults with Systemic Lupus Erythematosus We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults | Rheumatology | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input (...) Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults Caroline Gordon Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham,Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust,Rheumatology Department, University

2017 British Society for Rheumatology

17. Belimumab for treating active autoantibody-positive systemic lupus erythematosus

Belimumab for treating active autoantibody-positive systemic lupus erythematosus Belimumab for treating activ Belimumab for treating active e autoantibody-positiv autoantibody-positive systemic lupus e systemic lupus erythematosus erythematosus T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. (PubMed)

Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. Cardiovascular disease is common in patients with systemic lupus erythematosis (SLE) and lupus nephritis (LN). Up to 80% of children with SLE develop kidney disease, which is also associated with increased risk for cardiovascular disease and death compared to those without renal involvement. Hepcidin is an iron-regulatory protein which may contribute to atherosclerosis

Full Text available with Trip Pro

2019 PLoS ONE

19. Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus. (PubMed)

Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus. Currently there are 2 different classification criteria for systemic lupus erythematosus (SLE): American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (...) (cSLE) using a large, multiethnic cohort.We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Prospectively collected data from SickKids' Lupus Database were reviewed/validated against medical records prior to ACR and SLICC scoring based on cumulative symptoms up to the last visit. Sensitivities were compared using McNemar's test. Descriptive statistics were used to identify SLE features unique to each set of criteria and autoantibodies

2019 Journal of Rheumatology

20. Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. (PubMed)

Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. [This corrects the article DOI: 10.1371/journal.pone.0207926.].

Full Text available with Trip Pro

2019 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>